ARGX vs RPRX
argenx SE and Royalty Pharma plc, both Healthcare
argenx SE is the larger company at $55B against $30B. On trailing earnings RPRX is the cheaper of the two at a P/E of 32.9 against 53.5, a gap that is only a bargain if the two are growing at similar rates. Over the past year RPRX returned +71% against +56% for ARGX.
| Figure | ARGX | RPRX |
|---|---|---|
| Last close | $1047 | $61.80 |
| Market cap | $55B | $30B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 53.5 | 32.9 |
| 1-year return | +56% | +71% |
| 5-year return | +239% | +87% |
| Ryufin Smart Scoresector-relative, 1–10 | 7/10 | 7/10 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
argenx SE
Revenue of $2.5B in H2 2025, net income $877M.
Royalty Pharma plc
Revenue of $674M in Q2 2026, net income $18M. Its largest reported line is Financial Royalty Assets, 94% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or read the correlation.